生物科技
概述
Sidley is a leader in advising biotech innovators and investors throughout the lifecycle of their products and investments. Working closely with the firm’s lawyers in the United States, Europe and Asia, we have decades of experience in helping our clients raise funds and capital, conduct clinical trials, comply with GMP and anti-corruption rules, and protect and commercialize their intellectual property. We understand the issues innovators in the biotech industry face—from the science and technology to the business realities.
News & Insights
Sidley Lawyer Michael Borden To Speak on “The Biosecure Act: What Chinese Biotech and Life Sciences Companies Need To Know” WebinarThursday, December 18, 2025U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025U.S. FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and InvestigatorsDecember 4, 2025
活动
GoodLifeSci
GoodLifeSci
Global Life Sciences Update
U.S. FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and InvestigatorsDecember 4, 2025How Three Years of the Universal Proxy Card Rules Have Changed Proxy ContestsSeptember 9, 2025FDA Release of Complete Response Letters Raises Confidentiality, Disclosure Questions But Offers Insights for DevelopmentJuly 11, 2025EU Limits Chinese Participation in Medical Devices ProcurementJune 30, 2025
Global Life Sciences Update
Shareholder Activism Update
Food, Drug, and Medical Device Update
Global Arbitration, Trade and Advocacy
Sidley Lawyer Michael Borden To Speak on “The Biosecure Act: What Chinese Biotech and Life Sciences Companies Need To Know” WebinarThursday, December 18, 2025Swiss MedTech 2025Tuesday, September 2, 202526th Sidley China Life Sciences RoundtableWednesday, June 4, 2025 – Friday, June 6, 2025Sidley Healthcare Investment Conference 2024Tuesday, September 24, 2024
活动
活动
活动
活动
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025Navigating an Uncertain Market Amidst Cautious Optimism: Steps Biotech Companies Can Take to Hedge Against Financial FluctuationsNovember 18, 2025SEC Remains Focused on Public Disclosures Made By Life Sciences CompaniesOctober 29, 2025
GoodLifeSci
GoodLifeSci
GoodLifeSci
GoodLifeSci
Related Blogs
详情
We bring value to our clients in the following ways:
- Innovative approach—Our lawyers are experienced in the patent legal issues faced by biotech companies, as well as in counseling financial sponsors, lenders, venture capitalists and private equity clients on the variety of agreements and partnerships they may enter into. Harnessing the talent of the firm’s robust transactional and life sciences regulatory practices, we confront our clients’ most challenging issues with innovative solutions.
- Leaders in the industry—Sidley is at the forefront of the biotech movement with our “EYE ON BIO” series; events that feature perspectives on biotech innovation and investment around the world, with thought leaders from the business, legal, academic and medical communities.
- Deep industry experience—We are dedicated to providing practical advice regarding the unique disclosure and compliance issues biotech companies face. Our lawyers provide services in matters relating to the development, manufacture and marketing of products regulated by the Food and Drug Administration (FDA), the European Commission, the China Food and Drug Administration (CFDA) and other related government authorities.
- Diversified services—We assist biotech clients on a variety of complex matters, including: mergers and acquisitions, private equity, regulation, compliance and investigations, funding, competition, dispute resolution, tax, intellectual property, products liability and capital markets.
All Professionals
sort











